Home › Companies › APELLIS PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and APELLIS PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2024-2025
Explore APELLIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are APELLIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Paul Fonteyne | 98,837,712 | -- | -- | 5,320,270 | 5,506,458 | Majority: yes |
| Elect Director: Stephanie Monaghan O'Brien | 80,481,023 | -- | -- | 23,672,152 | 5,511,264 | Majority: yes |
| The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 109,564,727 | 56,762 | 42,951 | -- | -- | Majority: yes |
| The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers. | 93,573,357 | 10,540,010 | 44,708 | -- | 5,506,364 | Majority: yes |
Source: APELLIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-05 — read the filing on EDGAR.
Each item below shows how the 335 asset managers that disclosed a APELLIS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 10 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”): 93,573,357 for, 10,540,010 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,267,000 outstanding shares: 77% for, 9% against (86% of the company cast a for/against vote).
The 331 asset managers below cast 90% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,672,613 | 0 | 0 | 0 | For |
| Wellington | 14,440,788 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 11,607,425 | 0 | 0 | 0 | For |
| T. Rowe Price | 11,366,022 | 0 | 0 | 0 | For |
| Fidelity | 5,752,197 | 6,111 | 0 | 0 | For |
| BlackRock | 3,928,902 | 0 | 0 | 0 | For |
| State Street | 3,882,117 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 3,764,783 | 0 | 0 | 0 | For |
| JPMorgan | 3,134,027 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 0 | 3,044,200 | 0 | 0 | Against |
| Prudential/PGIM | 103,458 | 1,911,322 | 0 | 0 | Against |
| Hartford | 2,008,979 | 0 | 0 | 0 | For |
| Charles Schwab | 1,847,635 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,687,663 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 0 | 1,297,800 | 0 | 0 | Against |
| Octagon Capital Advisors LP | 1,151,356 | 0 | 0 | 0 | For |
| Invesco | 1,144,098 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,054,440 | 0 | 0 | 0 | For |
| Boxer Capital, LLC | 1,046,872 | 0 | 0 | 0 | For |
| Victory Capital | 1,028,186 | 0 | 0 | 0 | For |
| Fiera Capital Corp | 853,977 | 0 | 0 | 0 | For |
| EAGLE ASSET MANAGEMENT INC | 832,351 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 820,706 | 0 | 0 | 0 | For |
| Logos Global Management LP | 0 | 800,000 | 0 | 0 | Against |
| Jackson National | 742,685 | 0 | 0 | 0 | For |
Showing the 25 largest of 331 asset managers. See all 331 in the interactive database.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Paul Fonteyne”): 98,837,712 for, 5,320,270 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,267,000 outstanding shares: 82% for, 4% withheld (86% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (43,479,966 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,541,231 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,453,593 | 0 | 0 | 0 | For |
| Fidelity | 3,465,086 | 0 | 0 | 0 | For |
| Prudential/PGIM | 2,012,220 | 0 | 0 | 0 | For |
| Hartford | 2,008,979 | 0 | 0 | 0 | For |
| BlackRock | 1,530,474 | 0 | 0 | 0 | For |
| State Street | 1,251,217 | 0 | 1,384 | 0 | For |
| JPMorgan | 1,219,479 | 0 | 0 | 0 | For |
| Charles Schwab | 922,388 | 0 | 0 | 0 | For |
| Jackson National | 742,685 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 613,712 | 0 | 0 | 0 | For |
| Invesco | 534,726 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 447,683 | 0 | 0 | 0 | For |
| Victory Capital | 387,775 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 327,853 | 0 | 0 | 0 | For |
| Northwestern Mutual | 282,999 | 0 | 0 | 0 | For |
| TIAA | 265,577 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 259,677 | 0 | 0 | 0 | For |
| First Trust | 244,769 | 0 | 0 | 0 | For |
| PIONEER SERIES TRUST II | 226,807 | 0 | 0 | 0 | For |
| Brighthouse | 214,373 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 209,794 | 0 | 0 | 0 | For |
| Voya | 196,105 | 0 | 0 | 0 | For |
| Aberdeen | 189,813 | 0 | 0 | 0 | For |
| MassMutual | 184,448 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 4 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephanie Monaghan O'Brien”): 80,481,023 for, 23,672,152 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,267,000 outstanding shares: 66% for, 20% withheld (86% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (35,894,361 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,541,231 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,453,593 | 0 | 0 | 0 | For |
| Fidelity | 3,465,086 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,951,537 | 0 | 60,683 | 0 | For |
| Hartford | 2,008,979 | 0 | 0 | 0 | For |
| BlackRock | 1,530,474 | 0 | 0 | 0 | For |
| State Street | 13,334 | 0 | 1,239,267 | 0 | Abstain |
| JPMorgan | 1,219,479 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 922,388 | 0 | Abstain |
| Jackson National | 448,537 | 0 | 294,148 | 0 | For |
| CARILLON SERIES TRUST | 0 | 0 | 613,712 | 0 | Abstain |
| Invesco | 0 | 0 | 534,726 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 447,683 | 0 | Abstain |
| Victory Capital | 1,109 | 0 | 386,666 | 0 | Abstain |
| Bridge Builder Trust | 25,577 | 0 | 302,276 | 0 | Abstain |
| Northwestern Mutual | 282,999 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 265,577 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 259,677 | 0 | Abstain |
| First Trust | 0 | 0 | 244,769 | 0 | Abstain |
| PIONEER SERIES TRUST II | 0 | 0 | 226,807 | 0 | Abstain |
| Brighthouse | 6,764 | 0 | 207,609 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 209,794 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 196,105 | 0 | Abstain |
| Aberdeen | 0 | 0 | 189,813 | 0 | Abstain |
| MassMutual | 184,448 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 109,564,727 for, 56,762 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 121,267,000 outstanding shares: 90% for, 0.1% against (90% of the company cast a for/against vote).
The 93 asset managers below cast 99.9% of the shares they voted on this item FOR (43,522,895 for, 5,299 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,541,231 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,453,593 | 0 | 0 | 0 | For |
| Fidelity | 3,465,086 | 0 | 0 | 0 | For |
| Prudential/PGIM | 2,012,220 | 0 | 0 | 0 | For |
| Hartford | 2,008,979 | 0 | 0 | 0 | For |
| BlackRock | 1,530,474 | 0 | 0 | 0 | For |
| State Street | 1,252,601 | 0 | 0 | 0 | For |
| JPMorgan | 1,219,479 | 0 | 0 | 0 | For |
| Charles Schwab | 922,388 | 0 | 0 | 0 | For |
| Jackson National | 742,685 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 613,712 | 0 | 0 | 0 | For |
| Invesco | 534,726 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 447,683 | 0 | 0 | 0 | For |
| Victory Capital | 387,775 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 327,853 | 0 | 0 | 0 | For |
| Northwestern Mutual | 282,999 | 0 | 0 | 0 | For |
| TIAA | 265,577 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 259,677 | 0 | 0 | 0 | For |
| First Trust | 244,769 | 0 | 0 | 0 | For |
| PIONEER SERIES TRUST II | 226,807 | 0 | 0 | 0 | For |
| Brighthouse | 214,373 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 209,794 | 0 | 0 | 0 | For |
| Voya | 196,105 | 0 | 0 | 0 | For |
| Aberdeen | 189,813 | 0 | 0 | 0 | For |
| MassMutual | 184,448 | 0 | 0 | 0 | For |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Ranked by the number of APELLIS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 121,267,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 16.22% |
| 2 | Wellington | 11.91% |
| 3 | EcoR1 Capital, LLC | 9.57% |
| 4 | T. Rowe Price | 9.37% |
| 5 | Fidelity | 4.75% |
| 6 | BlackRock | 3.24% |
| 7 | State Street | 3.20% |
| 8 | Avoro Capital Advisors LLC | 3.10% |
| 9 | JPMorgan | 2.58% |
| 10 | JENNISON ASSOCIATES LLC | 2.51% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Wellington Management | 12.42% | 13F |
| Vanguard Group | 8.24% | 13F |
| Morgan Stanley | 7.95% | 13F |
| BlackRock | 5.17% | 13F |
| State Street | 2.40% | 13F |
| T. Rowe Price | 2.03% | 13F |
| Geode Capital | 1.39% | 13F |
| Citadel Advisors | 1.33% | 13F |
| Norges Bank | 0.77% | 13F |
| Charles Schwab | 0.76% | 13F |
Percentages above are of 121,267,000 shares outstanding, as reported by APELLIS PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from APELLIS PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At APELLIS PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 335 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,694 separate fund positions. On the most widely held item on that ballot — Approval of an advisory vote on executive compensation; and — FOR was 90% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: APELLIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-05.
APELLIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.